PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
Company Growth (employees)
Type
Public
HQ
South Plainfield, US
Founded
1998
Size (employees)
304 (est)+3%
Website
ptcbio.com
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, US

Key People/Management at PTC Therapeutics

Stuart Peltz

Stuart Peltz

Chief Executive Officer
Marcio Souza

Marcio Souza

Chief Operating Officer
Mark Boulding

Mark Boulding

Executive Vice President and Chief Legal Officer
Mary Harmon

Mary Harmon

Senior Vice President, Corporate Relations
Martin Rexroad

Martin Rexroad

Senior Vice President, Human Resources
Megan Sniecinski

Megan Sniecinski

Senior Vice President, Business Operations and Program Management
Christine Utter

Christine Utter

Principal Financial Officer and Treasurer
Neil Almstead

Neil Almstead

Executive Vice President, Research, Pharmaceutical Operations & Technology

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct
Show all (1)

PTC Therapeutics Financials and Metrics

PTC Therapeutics Financials

PTC Therapeutics's revenue was reported to be $82.7 m in FY, 2016
USD

Revenue (Q2, 2017)

48 m

Gross profit (Q2, 2017)

47.2 m

Gross profit margin (Q2, 2017), %

98%

EBIT (Q2, 2017)

(12.5 m)

Market capitalization (22-Dec-2017)

687.2 m

Cash (30-Jun-2017)

133 m

EV

695.4 m
PTC Therapeutics's current market capitalization is $687.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

34.7 m25.2 m36.8 m82.7 m

Revenue growth, %

(27%)46%125%

EBIT

(45.4 m)(99.4 m)(167.1 m)(132.1 m)

EBIT margin, %

(131%)(394%)(455%)(160%)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

9.2 m1.7 m1.7 m7.5 m6.8 m9.8 m18.9 m15.6 m23 m26.5 m48 m

Cost of goods sold

39 k758 k

Gross profit

26.5 m47.2 m

Gross profit Margin, %

100%98%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.4 m49.7 m58 m58.3 m

Accounts Receivable

11.1 m24.9 m

Inventories

1.6 m3.9 m5.9 m4.7 m

Current Assets

145 m323.6 m355.9 m261.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

24 m115.9 m21.2 m52.9 m36.8 m29.2 m140.7 m40.2 m35.7 m50.3 m54.1 m133 m

Accounts Receivable

22.6 m19.8 m27.4 m32.2 m33.8 m

Inventories

1.4 m6.9 m

Current Assets

160.1 m249.4 m230.3 m213.5 m289.8 m264.6 m384.2 m326.4 m297.4 m280.6 m240.7 m227 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(51.6 m)(93.8 m)(170.4 m)(142.1 m)

Depreciation and Amortization

2.4 m2.2 m2.9 m3.3 m

Accounts Receivable

(6.9 m)(14.8 m)

Inventories

(760.5 k)(2.3 m)(2.1 m)1.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(33.7 m)(14.1 m)(39.2 m)(66.5 m)(37.9 m)(76.3 m)(119.5 m)(41.2 m)(80.1 m)(115.3 m)(29.1 m)(46.5 m)

Depreciation and Amortization

1.8 m588 k1.2 m1.7 m634 k1.3 m2.1 m849 k1.7 m2.5 m612 k1.4 m

Accounts Receivable

(10.7 m)(8.5 m)(16 m)(6.7 m)(6.8 m)

Inventories

(1.4 m)
Y, 2017

EV/EBIT

-55.6 x

EV/CFO

-44.6 x

Financial Leverage

2.3 x
Show all financial metrics

PTC Therapeutics Market Value History

PTC Therapeutics's Web-traffic and Trends

PTC Therapeutics Online and Social Media Presence

PTC Therapeutics Company Life and Culture

You may also be interested in